Location of Repository

Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes

By Gary R. MacVicar and Maha H. A. Hussain

Abstract

Prostate cancer remains a significant health concern for men in the USA as it is a leading cancer diagnosis and a cause of death. With the use of prostate-specific antigen or screening, a stage migration has occurred with an increase in the number of men diagnosed with early-stage disease. The optimal primary management of these men is evolving, but despite adequate local treatment a significant percentage will develop either biochemical or clinical evidence of recurrent disease. Several criteria for risk stratification have been developed, thus, improving the ability to identify a high-risk population. Small studies have been reported demonstrating the feasibility of neoadjuvant or adjuvant chemotherapy in conjunction with either radiation or radical prostatectomy in this high-risk population, and large phase III studies are ongoing. With the advent of life-prolonging chemotherapy in the hormone-refractory setting, attention must now also be given to early-stage disease so as to develop multi-modality approaches with the hope of increasing survival and ultimately providing a cure

Publisher: Springer-Verlag
Year: 2005
DOI identifier: 10.1007/s00280-005-0103-7
OAI identifier: oai:deepblue.lib.umich.edu:2027.42/46931
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/2027.42/... (external link)
  • http://dx.doi.org/10.1007/s002... (external link)
  • http://www.ncbi.nlm.nih.gov/si... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.